Quercetin: Bioavailability, Anti-Inflammatory Evidence, and Food Sources

Medical disclaimer: This article is written for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting any supplement, particularly if you are pregnant, breastfeeding, taking prescription medications, or managing a chronic health condition. Individual responses to dietary compounds vary.

What Is Quercetin?

Quercetin is a plant pigment — technically a polyphenolic flavonoid — and one of the most widely consumed dietary compounds in the human diet. It belongs to the flavonol subclass of flavonoids, a group distinguished by a hydroxyl group at the 3-position of the flavone backbone. This structural feature gives quercetin its characteristic yellow colour (the name derives from the Latin quercetum, meaning oak forest) and underpins many of its biological activities.

In plants, quercetin functions as a UV filter, antimicrobial defence, and signalling molecule. In humans, it has attracted decades of research attention for its antioxidant capacity and, more recently, for its measurable effects on inflammatory pathways, immune regulation, and antiviral defence.

Understanding quercetin requires distinguishing between two structural forms. The aglycone form (free quercetin, no sugar attached) is the biologically active molecule studied in mechanistic research. The glycoside forms — quercetin bonded to sugar molecules like glucose, rhamnose, or rutin — are the predominant dietary versions found in whole food. Glycoside forms have substantially different absorption kinetics than the aglycone, and this distinction matters considerably when evaluating supplements against food sources.

---

Food Sources and Quercetin Content

Quercetin is distributed across a wide range of plant foods, but concentrations vary dramatically by species, variety, growing conditions, and preparation method. Cooking, particularly boiling, can reduce quercetin content by 30–50% through leaching into cooking water, while dry heat has less impact.

Capers are the single richest dietary source, providing approximately 234 mg of quercetin per 100 g (raw). This exceptional concentration reflects the caper's role as a flower bud — plant tissues in reproductive phases tend to accumulate higher flavonoid loads as a defence against environmental stress.

Raw onions deliver roughly 39 mg per 100 g, with outer rings and red varieties consistently higher than white. Onion remains the most practically significant dietary source for most populations simply because consumption volumes are far greater than capers. Quercetin in onion is predominantly present as quercetin-4'-glucoside and quercetin-3,4'-diglucoside — glycoside forms that influence how well it absorbs (more on this below).

Apples contain around 4 mg per 100 g, concentrated primarily in the skin. Peeling an apple removes the majority of its quercetin. Broccoli provides approximately 3 mg per 100 g, kale ranges from 5 to 23 mg per 100 g depending on variety and season, and green tea contributes 2–3 mg per 100 mL per cup, though tea is also a source of other flavonoids including catechins and kaempferol that may act synergistically.

For context, average dietary quercetin intake in Western populations has been estimated at 10–30 mg per day, primarily from onions, apples, and tea. High-consumer populations in countries with greater onion and leek intake may reach 50–80 mg/day from food alone.

---

The Bioavailability Problem

The research literature on quercetin's biological effects is extensive and often compelling — but a critical caveat runs through most supplement studies: standard quercetin supplements are poorly absorbed.

Quercetin aglycone, the form used in most encapsulated supplements, has an estimated oral bioavailability of just 1–7% in humans. This means that the vast majority of a standard quercetin capsule passes through the gastrointestinal tract without entering systemic circulation. The compound is hydrophobic, has low aqueous solubility, and is subject to extensive first-pass metabolism in the intestinal wall and liver. Much of what does absorb is rapidly conjugated to glucuronide and sulfate groups, which may or may not retain biological activity depending on the target tissue.

This is not a minor limitation. If a study reports that 500 mg of quercetin aglycone produced a meaningful clinical effect, the amount actually reaching target tissues was likely in the low single-digit milligram range. This makes interpretation of dose-response relationships difficult and explains why some human trials show modest or inconsistent results.

Quercetin Glycosides: Better Absorption from Food

Paradoxically, the glycoside forms found in food often absorb more efficiently than the aglycone form used in supplements. Quercetin-3-glucoside (isoquercetin), abundant in onion, is transported across the intestinal brush border via the SGLT1 sodium-glucose co-transporter — the same transporter used for glucose uptake. This active transport mechanism gives quercetin glycosides a meaningful absorption advantage over the passive diffusion that the aglycone relies on.

Studies comparing quercetin sources have found quercetin from onion to produce significantly higher plasma concentrations than equivalent doses of quercetin aglycone, supporting the idea that food-matrix quercetin glycosides have superior bioavailability to most supplemental forms.

Quercetin Phytosome: A Formulation Advance

The most well-documented solution to the bioavailability limitation is the quercetin phytosome formulation, commercially known as QUERCEFIT, developed by Indena (Italy). In phytosome technology, quercetin is complexed with sunflower phosphatidylcholine — a phospholipid that dramatically improves both aqueous dispersion and intestinal membrane penetration by mimicking the lipid bilayer environment.

A pharmacokinetic study by Riva et al. (2019) directly compared standard quercetin aglycone against QUERCEFIT in healthy volunteers. The phytosome formulation demonstrated approximately 20-fold greater bioavailability than the unformulated aglycone — a clinically meaningful difference. Plasma quercetin concentrations achieved with the phytosome at 250 mg were comparable to those produced by 4,000–5,000 mg of standard quercetin.

This pharmacokinetic advantage means that phytosome-based products can be used at much lower doses (250–500 mg/day) while delivering systemic exposure that standard formulations simply cannot match. For anyone considering quercetin supplementation, the delivery form is arguably as important as the labelled dose.

---

Anti-Inflammatory Mechanisms

Quercetin's anti-inflammatory activity is multi-pathway, which partly explains why it has been investigated across such a wide range of conditions. It does not act as a single-target drug — it modulates several intersecting inflammatory networks simultaneously.

NF-κB inhibition is the most extensively characterised mechanism. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a master transcription factor controlling expression of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and IL-8. Quercetin inhibits upstream kinases (IKKβ) that normally phosphorylate and degrade the IκB inhibitor, preventing NF-κB from entering the nucleus and activating inflammatory gene transcription. This mechanism is well established across cell studies and animal models, and represents the most likely explanation for quercetin's broad anti-inflammatory profile.

NLRP3 inflammasome suppression represents a more recently characterised target. The NLRP3 inflammasome is an intracellular multiprotein complex that processes pro-IL-1β into active IL-1β, a cytokine central to acute inflammatory responses and implicated in conditions ranging from gout to neuroinflammation. Quercetin has been shown to inhibit NLRP3 activation in macrophage models, with potential implications for inflammatory conditions where this pathway plays a driving role.

COX-2 inhibition positions quercetin alongside conventional non-steroidal anti-inflammatory drugs (NSAIDs), though its affinity for COX-2 is considerably weaker than pharmaceutical inhibitors. Quercetin appears to primarily downregulate COX-2 gene expression rather than directly binding the enzyme active site — a distinction that may contribute to a gentler tolerability profile.

Mast cell stabilisation is particularly relevant for individuals with histamine intolerance, allergic conditions, or mast cell activation syndrome (MCAS). Quercetin inhibits the release of histamine and other mediators from IgE-sensitised mast cells, and reduces degranulation in response to allergen challenge. For people managing chronic mast cell-related symptoms, this mechanism gives quercetin especially practical clinical relevance, and it appears frequently in protocols for allergy and MCAS support.

---

Clinical Evidence

Cardiovascular Risk Factors — Boots et al. (2008)

A systematic review by Boots and colleagues evaluated human studies on quercetin and cardiovascular-related endpoints. The review found evidence supporting quercetin's antioxidant and anti-inflammatory activity in human subjects, with effects on endothelial function, LDL oxidation susceptibility, and inflammatory markers. The authors noted important caveats around bioavailability variability across supplement types and identified gaps in long-term randomised controlled trial data.

Blood Pressure Reduction — Egert et al. (2009)

One of the more compelling human trials was conducted by Egert and colleagues, who administered 150 mg/day of quercetin aglycone to overweight subjects with metabolic syndrome characteristics in a randomised, double-blind, placebo-controlled crossover design. In the subgroup with hypertension (stage 1), quercetin produced a statistically significant reduction in systolic blood pressure of 2.6 mmHg compared to placebo. No significant effect was observed in normotensive participants.

While 2.6 mmHg may appear modest, at a population level this magnitude of effect is clinically meaningful — comparable to what is achievable with dietary sodium restriction. Notably, this was achieved with a low-bioavailability aglycone formulation, suggesting higher plasma concentrations via improved formulations could yield greater effects.

Mlcek 2016 Systematic Review

A 2016 systematic review by Mlcek and colleagues evaluated the breadth of quercetin research across anti-inflammatory, antioxidant, antiviral, anticancer, and cardiovascular domains. The review consolidated evidence supporting quercetin's utility as a functional food compound and highlighted food-matrix effects on bioavailability, consistent with observations that quercetin from onions consistently outperforms supplemental aglycone on pharmacokinetic metrics.

---

Antiviral Effects and the Zinc Ionophore Mechanism

Quercetin received renewed research attention during the COVID-19 pandemic, largely due to its proposed activity as a zinc ionophore — a compound that facilitates the transport of zinc ions across lipid membranes into the intracellular space.

Zinc has established antiviral properties, partly through inhibition of RNA-dependent RNA polymerase, the enzyme RNA viruses use to replicate their genetic material. The challenge is that extracellular zinc does not readily enter cells without a carrier molecule. Quercetin's ionophore properties theoretically allow it to shuttle zinc into cells, raising intracellular concentrations capable of impairing viral replication. Similar ionophore activity is documented for hydroxychloroquine, a drug that attracted significant pandemic-era attention for related reasons.

A clinical study by Di Pierro and colleagues (2021) investigated quercetin phytosome combined with zinc supplementation in mild-to-moderate COVID-19 patients as an adjunct to standard care. The trial reported faster symptom resolution and fewer hospitalisations in the quercetin-zinc group. The study had limitations including its open-label design and modest sample size, but it provided early human evidence for the combination and aligned with the mechanistic rationale.

More broadly, quercetin has demonstrated inhibitory effects against multiple RNA viruses in vitro, including influenza, rhinovirus, and respiratory syncytial virus. Mechanisms extend beyond zinc ionophore activity to include direct binding of viral proteases and modulation of host cell entry pathways. Human trial evidence in this domain remains preliminary but is accumulating.

---

Quercetin and Bromelain: A Synergistic Pairing

Bromelain is a proteolytic enzyme complex derived from pineapple stems, with its own anti-inflammatory properties via modulation of cytokine expression and fibrinogen processing. When combined with quercetin, bromelain serves an additional practical role: it enhances quercetin absorption by breaking down intestinal mucoproteins that would otherwise create a physical barrier limiting quercetin's access to the epithelial surface.

This synergy has made quercetin-bromelain combination products a popular supplement format, particularly for immune and allergy support. The pairing represents a pragmatic bioavailability-enhancement strategy that predates phytosome technology and remains widely used. From a practical standpoint, a quercetin-bromelain combination using standard aglycone quercetin may partially close the bioavailability gap, though direct pharmacokinetic comparisons with phytosome formulations remain limited.

For a deeper look at how polyphenols interact with gut physiology to produce systemic effects, the article on polyphenols and the microbiome covers the mechanistic overlap in more detail.

---

Dosing Considerations

The appropriate quercetin dose depends significantly on formulation type:

Standard quercetin aglycone: Studies have used 150–1,000 mg/day, with most human trials in the 500–1,000 mg/day range. Given the 1–7% bioavailability, effective systemic exposure at these doses remains low. Splitting doses across the day and consuming with a fatty meal improves absorption modestly by improving solubility in the gut lumen.

Quercetin phytosome (QUERCEFIT): Due to the approximately 20-fold bioavailability advantage, 250–500 mg/day of phytosome quercetin likely delivers greater systemic exposure than 1,000 mg/day of standard aglycone. This is the formulation most likely to replicate plasma levels associated with positive clinical outcomes.

Food-first approach: A diet consistently rich in quercetin-containing whole foods — daily onion consumption, regular apple eaten with skin, kale, broccoli, and green tea — can realistically deliver 50–100 mg/day of quercetin in glycoside forms with superior absorption kinetics. While this falls short of supplemental doses, the food matrix provides co-factors, fibre, and additional phytochemicals that may amplify functional effects and are absent from isolated supplements.

Those exploring quercetin alongside broader connective tissue and collagen support may find it useful to read the evidence review on collagen peptides and nutrition, as several collagen-supporting dietary strategies overlap with flavonoid-rich food patterns. For an integrated dietary framework that places quercetin-rich foods within a broader anti-inflammatory eating pattern, the anti-inflammatory diet protocol covers the foundational principles in practical detail.

---

Practical Summary

Quercetin is a well-characterised flavonoid with genuine anti-inflammatory, antioxidant, and emerging antiviral evidence — but the benefits largely depend on how much actually enters the bloodstream. Standard aglycone supplements have historically underperformed on bioavailability terms, while quercetin glycosides from food (particularly onions) and phytosome formulations represent meaningfully better delivery options backed by pharmacokinetic data.

The mechanistic case is strong: NF-κB inhibition, NLRP3 suppression, mast cell stabilisation, and zinc ionophore activity give quercetin a plausible basis across several inflammatory and immune conditions. Human clinical data support modest but real blood pressure effects, and the zinc combination shows early promise in viral infection management.

For practical supplementation, phytosome-formulated quercetin is the evidence-based choice for those prioritising bioavailability. The quercetin-bromelain combination remains a reasonable alternative. And for those who prefer a food-first strategy, building a diet around high-quercetin whole foods — with raw or lightly cooked onion as a daily staple — provides a consistent, cost-effective, and well-absorbed baseline that no capsule can fully replicate in terms of synergistic nutrition.

The broader peptide and nutraceutical research landscape, including compounds that work alongside flavonoids for immune and inflammatory support, is covered in depth at RetaLABS Research.

---

Key References

• Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008;585(2-3):325-337.
• Egert S, Bosy-Westphal A, Seiberl J, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype. Br J Nutr. 2009;102(7):1065-1074.
• Mlcek J, Jurikova T, Skrovankova S, Sochor J. Quercetin and its anti-allergic immune response. Molecules. 2016;21(5):623.
• Riva A, Ronchi M, Petrangolini G, Bosisio S, Allegrini P. Improved oral absorption of quercetin from quercetin phytosome, a new delivery system based on food grade lecithin. Eur J Drug Metab Pharmacokinet. 2019;44(2):169-177.
• Di Pierro F, Iqtadar S, Khan A, et al. Potential clinical benefits of quercetin in the early stage of COVID-19: results of a second, pilot, randomized, controlled and open-label clinical trial. Int J Gen Med. 2021;14:2807-2816.